BRAF V600E-mutant Colorectal Cancer Study of Encorafenib Taken With Cetuximab Plus or Minus Chemotherapy (BREAKWATER)
Status:
Recruiting
Trial end date:
2026-11-15
Target enrollment:
Participant gender:
Summary
To evaluate whether encorafenib plus cetuximab (EC), alone or in combination with
chemotherapy, can improve clinical outcomes relative to current standard of care chemotherapy
in participants with previously untreated BRAF V600E-mutant mCRC
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Collaborators:
Merck KGaA, Darmstadt, Germany Ono Pharmaceutical Co. Ltd